
ECYT
Other · Other
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2018
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 7, 2018 | Time not confirmed | -0.16 | -0.17 | -6.3% |
| Aug 1, 2018 | Time not confirmed | -0.17 | -0.17 | 0.0% |
| May 9, 2018 | Time not confirmed | -0.19 | -0.16 | +15.8% |
| Feb 26, 2018 | Time not confirmed | -0.16 | -0.18 | -12.5% |
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose…